Cancer metastasis is the end result of a complex series of biological events that lead to the formation of clinically significant secondary tumors at distant sites. Clinical evidence demonstrates that such sites are not randomly located, and certain malignant tumors show a tendency to develop metastases in specific organs (e.g., brain, liver, and lungs). 1 However, an appropriate animal model to characterize the hematogenous nature (i.e., originating in blood) of transplantable human-cancer-cell lines is not available for metastatic cells, while profiling data of hematogenous metastasis has not attracted sufficient scientific attention to improve understanding.
Figure 1. Representative metastatic images of human-cancer-cell lines in nonobese diabetic/severe combined-immunodeficiency mice. Luciferase-expressing cells were injected into the left cardiac ventricle under fine-ultrasonography guidance. In and ex vivo bioluminescence imaging was conducted for (left) HT-29 colon and (middle) MDA-MB-231 breast cancer, and (right) Mewo melanoma cells 30-40 days after tumor implantation. (right) Black dots in the brain represent metastasis of Mewo cells.
To date, cancer-cell injection into mice has been done easily through the tail vein. However, this route is not beneficial for systemic cell delivery because most of the sizable injected cells are trapped in the lung capillaries. To overcome this and systemically deliver cells via arteries, many scientists have blindly tried injections into the left ventricle (heart chamber). Even veteran technicians have blindly been injecting cells into a very narrow space in the mouse heart. However, high-resolution ultrasonography (US), developed specifically for small-animal imaging, now provides clear identification of areas of interest within the myocardial wall (i.e., of the heart muscle) and allows
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precise, site-directed cell injection. Therefore, using fine-US guidance, we have successfully realized accurate and reproducible cardiac-cell injection into mice.
We have generated more than 30 luciferase-expressing human-cancer-cell lines using retroviral transduction. We inoculated these cells into the left cardiac ventricle of nonobese diabetic/severe combined-immunodeficiency (NOD/SCID) mice under fine-US guidance. BLI was conducted for each cell line, and representative organs (e.g., brain, liver, lungs, lymph nodes, bones, and gastrointestinal tract) were then inspected ex vivo. We observed cancer-cell-type-dependent metastasis to specific organs even in mice (beyond the species): see Figure 1 . For instance, human colon-cancer HT-29 cells accumulated significantly in the liver of mice, while human-melanoma cell lines showed frequent metastasis to brain, lungs, and lymph nodes in the mouse model. For breast-cancer MDA-MB-231 cells, metastasis was observed to the bone in addition to the brain, lungs, and lymph nodes. Notably, reflecting the clinical features of melanoma, breast, and lung cancer, some cell lines showed preferential metastasis to the brain of mice.
Characteristics common to both tumor cells and normal stem cells appear to exist, referred to as stemness. The hallmark traits of stem cells-self-renewal and differentiation capacity-are reflected by the high proliferative capacity and phenotypic plasticity of tumor cells. 3 Since the initial concept of cancer stem cells in solid tumors was established using NOD/SCID mice, we have had to employ animals to apply luciferase-expressing cell behavior to the theory of cancer stem cells. Our recent BLI-based experimentation suggests that a subpopulation of cancer stem cells is essential for organ-selective cancer metastasis. 4 Approximately 10-20% of all systemic malignancies will eventually metastasize to the brain. 5 Despite this high frequency of brain tumors, an accepted approach for effective treatment is still lacking. Accumulating clinical data suggest that the interaction between chemokines (proteins) and their receptors is a critical component for regulation of tumor progression and metastasis in many cancer types, 1 and that the CXCR4/CXCL12 pathway is involved. 1 However, the pathophysiology in brain metastasis is not fully understood because of the difficulty of creating appropriate animal models. Therefore, BLI combined with highfrequency US imaging should allow various preclinical studies at the tumor/normal-brain interface.
Combining cell resources with an appropriate animal model, our goal for the immediate future, will promote a better and more profound understanding of human-cancer-cell biology. Advances in optical imaging should provide a new platform to accelerate development of therapeutic strategies for human cancer.
